Rui Dai, Yiting Cai, Jun Li, Xiaoman Liu, Qian Fu, Min Huang, Changxi Wang, Pan Chen
{"title":"Dosing strategy of tacrolimus when co-administered with <i>Wuzhi</i> tablet in renal transplant recipients.","authors":"Rui Dai, Yiting Cai, Jun Li, Xiaoman Liu, Qian Fu, Min Huang, Changxi Wang, Pan Chen","doi":"10.5414/CP204561","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Tacrolimus (TAC) is a first-line immunosuppressant to prevent allograft rejection. <i>Wuzhi</i> tablet is widely used as a TAC-sparing agent in China that could significantly elevate TAC exposure. However, insufficient data support the dose recommendation of TAC when co-administered with <i>Wuzhi</i>.</p><p><strong>Materials and methods: </strong>A total of 305 adult renal transplant patients with 2,541 TAC trough concentrations (C<sub>0</sub>) were enrolled for population pharmacokinetic (PPK) modeling. <i>CYP3A5</i> polymorphism was genotyped, and corresponding clinical factors were recorded. Nonlinear mixed-effects modeling and Monte Carlo simulation were used for dose recommendation. PK parameters were calculated based on one-compartment model with first-order absorption and elimination.</p><p><strong>Results: </strong>The estimated total clearance (CL/F) and volume of distribution (V<sub>d</sub>/F) of TAC were 23.84 L/h and 1,075.96 L, respectively. <i>Wuzhi</i>, <i>CYP3A5</i> genotype, hematocrit (HCT), and weight were found to have a significant influence on CL/F. CL/F was significantly lower in the individuals who were <i>CYP3A5</i> non-expressers and received TAC together with <i>Wuzhi</i>. <i>CYP3A5</i> genotype (expressers or non-expressers), body weight (40 - 80 kg), and hematocrit (20 - 40%) were selected as the specific clinical scenarios, and the starting dose of TAC ranged from 1.5 to 4.5 mg when co-administered with <i>Wuzhi</i>.</p><p><strong>Conclusion: </strong>We establish a TAC PPK model comprising <i>Wuzhi</i> as a covariate in renal transplant recipients and recommend an initial dose of TAC when co-administered with <i>Wuzhi</i>, which could provide reference for the individualized regimens of TAC.</p>","PeriodicalId":13963,"journal":{"name":"International journal of clinical pharmacology and therapeutics","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of clinical pharmacology and therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5414/CP204561","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Tacrolimus (TAC) is a first-line immunosuppressant to prevent allograft rejection. Wuzhi tablet is widely used as a TAC-sparing agent in China that could significantly elevate TAC exposure. However, insufficient data support the dose recommendation of TAC when co-administered with Wuzhi.
Materials and methods: A total of 305 adult renal transplant patients with 2,541 TAC trough concentrations (C0) were enrolled for population pharmacokinetic (PPK) modeling. CYP3A5 polymorphism was genotyped, and corresponding clinical factors were recorded. Nonlinear mixed-effects modeling and Monte Carlo simulation were used for dose recommendation. PK parameters were calculated based on one-compartment model with first-order absorption and elimination.
Results: The estimated total clearance (CL/F) and volume of distribution (Vd/F) of TAC were 23.84 L/h and 1,075.96 L, respectively. Wuzhi, CYP3A5 genotype, hematocrit (HCT), and weight were found to have a significant influence on CL/F. CL/F was significantly lower in the individuals who were CYP3A5 non-expressers and received TAC together with Wuzhi. CYP3A5 genotype (expressers or non-expressers), body weight (40 - 80 kg), and hematocrit (20 - 40%) were selected as the specific clinical scenarios, and the starting dose of TAC ranged from 1.5 to 4.5 mg when co-administered with Wuzhi.
Conclusion: We establish a TAC PPK model comprising Wuzhi as a covariate in renal transplant recipients and recommend an initial dose of TAC when co-administered with Wuzhi, which could provide reference for the individualized regimens of TAC.
期刊介绍:
The International Journal of Clinical Pharmacology and Therapeutics appears monthly and publishes manuscripts containing original material with emphasis on the following topics: Clinical trials, Pharmacoepidemiology - Pharmacovigilance, Pharmacodynamics, Drug disposition and Pharmacokinetics, Quality assurance, Pharmacogenetics, Biotechnological drugs such as cytokines and recombinant antibiotics. Case reports on adverse reactions are also of interest.